Literature DB >> 14718799

Techniques for the neurological examination of taxane-induced neuropathy.

Shozo Ohsumi1, Yoshihide Sunada.   

Abstract

Taxanes are considered to be the key drugs in the treatment of breast cancer. Although physicians who treat patients with breast cancer have rarely seen patients with neuropathy as an adverse effect of treatment before the advent of taxanes, patients with breast cancer who are treated with taxanes frequently exhibit peripheral neuropathy. As peripheral neuropathy often causes deterioration of the quality of life of patients, it is very important to precisely assess the extent of peripheral neuropathy at an early stage. Clinical oncologists should be familiar with the techniques of neurological examination. In this article we describe the basic techniques for the neurological examination of patients with taxane-induced peripheral neuropathy. In the hope of facilitating the precise evaluation of taxane-induced peripheral neuropathy, the items of neurological examinations in this article are described with reference to the physician neuroexamination form (PNEF) designed by BioNumerik Pharmaceuticals Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718799     DOI: 10.1007/bf02968009

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

1.  Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Authors:  Katsumasa Kuroi; Kojiro Shimozuma; Yasuo Ohashi; Kazufumi Hisamatsu; Norikazu Masuda; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Shozo Ohsumi; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2008-12-17       Impact factor: 3.603

2.  Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.

Authors:  Kojiro Shimozuma; Yasuo Ohashi; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Katsumasa Kuroi; Shozo Ohsumi; Haruhiko Makino; Noriyuki Katsumata; Masaru Kuranami; Kimito Suemasu; Toru Watanabe; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2012-05-15       Impact factor: 3.603

3.  Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

Authors:  Kojiro Shimozuma; Yasuo Ohashi; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Katsumasa Kuroi; Shozo Ohsumi; Haruhiko Makino; Hirohumi Mukai; Noriyuki Katsumata; Yoshihide Sunada; Toru Watanabe; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2009-03-28       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.